Palatability and physical properties of potassium-binding resin RDX7675: comparison with sodium polystyrene sulfonate.
- Vanessa Zann,
- John McDermott,
- Jeffrey W Jacobs,
- James P Davidson,
- Fangling Lin,
- Paul Korner,
- Robert C Blanks,
- David P Rosenbaum
Drug Des Devel Ther 2017 6;11:2663-2673. Epub 2017 Sep 6.
Ardelyx Inc., Fremont, CA, USA.
Background: Hyperkalemia is a potentially life-threatening condition that patients with heart failure or chronic kidney disease, especially those taking renin-angiotensin-aldosterone system inhibitors, are at high risk of developing. Sodium polystyrene sulfonate (SPS), a current treatment, binds potassium within the gastrointestinal tract to reduce potassium absorption. However, poor palatability limits its long-term use. Read More